Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 ...

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...